Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice

Table 2 Results of IMBrave 150 trial

Results	Atezolizumab and bevacizumab arm	Sorafenib arm	Statistically significant
Estimated OS at 6 mo (%)	84.8	72.2
Estimated OS at 12 mo (%)	67.2	54.6
PFS (mo)	6.8	4.3	HR for progression or death was 0.59 (0.47-0.76) P < 0.0001
Confirmed ORR as per independent mRECIST assessment (%)	27.3	11.9
As per HCC specific mRECIST CR (%)	5.5	-
Disease Control Rate (ORR + SD) (%)	73.6	55.3

HCC: Hepatocellular carcinoma; OS: Overall survival; PFS: Progression free survival; ORR: Objective response rate; mRECIST: Modified response evaluation criteria in solid tumours.